Email Alert | RSS

Journal of Peking University (Health Sciences) ›› 2021, Vol. 53 ›› Issue (6): 1026-1031. doi: 10.19723/j.issn.1671-167X.2021.06.003

Previous Articles     Next Articles

Effect of chemokines CXCL9 and CXCL10 on bone erosion in patients with rheumatoid arthritis

ZHONG Hua,XU Li-ling,BAI Ming-xin,SU Yin()   

  1. Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis, Beijing 100044, China
  • Received:2021-07-28 Online:2021-12-18 Published:2021-12-13
  • Contact: Yin SU E-mail:suyin0921@163.com
  • Supported by:
    National Natural Science Foundation of China(81671609);Beijing Scientific Program(Z191100006619111)

RICH HTML

 19   

PDF (PC)

104

Abstract:

Objective: To detect the serum level of soluble chemokines CXCL9 and CXCL10 in patients with rheumatoid arthritis (RA), and to analyze their correlation with bone erosion, as well as the clinical significance in RA. Methods: In the study, 105 cases of RA patients, 90 osteoarthritis (OA) patients and 25 healthy controls in Peking University People’s Hospital were included. All the clinical information of the patients was collected, and the serum CXCL9 and CXCL10 levels of both patients and healthy controls were measured by enzyme-linked immune sorbent assay (ELISA). CXCL9 and CXCL10 levels among different groups were compared. The correlation between serum levels with clinical/laboratory parameters and the occurrence of bone erosion in RA were analyzed. Independent sample t test, Chi square test, Mann-Whitney U test, Spearman’s rank correlation and Logistic regression were used for statistical analysis. Results: The levels of CXCL9 and CXCL10 were significantly higher in the RA patients [250.02 (126.98, 484.29) ng/L, 108.43 (55.16, 197.17) ng/L] than in the OA patients [165.05 (75.89, 266.37) ng/L, 69.00 (33.25, 104.74) ng/L] and the health controls [79.47 (38.22, 140.63) ng/L, 55.44 (18.76, 95.86) ng/L] (all P<0.01). Spearman’s correlation analysis showed that the level of serum CXCL9 was positively correlated with swollen joints (SJC), rheumatoid factor (RF) and disease activity score 28 (DAS28) (r=0.302, 0.285, 0.289; P=0.009, 0.015, 0.013). The level of serum CXCL10 was positively correlated with tender joints (TJC), SJC, C-reactive protein (CRP), immunoglobulin (Ig) A, IgM, RF, anti-cyclic citrullinated peptide antibody (ACPA), and DAS28 (r=0.339, 0.402, 0.269, 0.266, 0.345, 0.570, 0.540, 0.364; P=0.010, 0.002, 0.043, 0.045, 0.009, <0.001, <0.001, 0.006). Serum CXCL9 and CXCL10 levels in the RA patients with bone erosion were extremely higher than those without bone erosion [306.84 (234.02, 460.55) ng/L vs. 149.90 (75.88, 257.72) ng/L, 153.74 (89.50, 209.59) ng/L vs. 54.53 (26.30, 83.69) ng/L, respectively] (all P<0.01). Logistic regression analysis showed that disease duration, DAS28 and serum level of CXCL9 were correlated with bone erosion in the RA patients (P<0.05). Conclusion: Serum levels of CXCL9 and CXCL10 were remarkably elevated in patients with RA, and correlated with disease activities and occurrence of bone erosion. Chemokines CXCL9 and CXCL10 might be involved in the pathogenesis and bone destruction in RA.

Key words: Rheumatoid arthritis, Bone erosion, Chemokine CXCL9, Chemokine CXCL10

CLC Number: 

  • R593.22

Figure 1

Serum levels of CXCL9 and CXCL10 in RA patients compared with osteoarthritis and healthy control groups RA, rheumatoid arthritis; OA, osteoarthritis; HC, healthy controls."

Table 1

Correlation between serum CXCL9 and CXCL10 levels with clinical characteristics and laboratory parameters in RA patients"

Characteristics CXCL9 CXCL10
r P r P
SJC 0.302 0.009 0.402 0.002
TJC 0.160 0.176 0.339 0.010
ESR 0.145 0.222 0.201 0.135
CRP 0.076 0.523 0.269 0.043
IgA 0.161 0.175 0.266 0.045
IgG 0.067 0.571 0.192 0.153
IgM 0.229 0.051 0.345 0.009
RF 0.285 0.015 0.570 <0.001
ACPA 0.031 0.793 0.540 <0.001

Figure 2

Correlation between serum CXCL9 and CXCL10 levels with disease activities in RA patients DAS28, disease activity score 28; RA, rheumatoid arthritis."

Table 2

Clinical and biochemical characteristics of RA patients with or without bone erosion"

Items All subjects Without bone erosion With bone erosion P value
Patients, n 52 17 35
Gender, n
Female 38 12 26 0.778
Male 14 5 9
Age/years 56 (52, 66) 55 (51, 66) 57 (52, 70) 0.667
Disease duration/month 60 (21, 204) 36 (8, 66) 84 (24, 240) 0.010
SJC, n 4 (1, 8) 2 (0, 8) 5 (2, 8) 0.234
TJC, n 4 (1, 8) 5 (2, 8) 2 (1, 7) 0.169
ESR/(mm/h) 52 (24, 100) 33 (13, 88) 61 (36, 102) 0.077
CRP/(mg/L) 21.30 (6.42, 53.25) 11.40 (3.07, 48.95) 30.90 (9.10, 53.80) 0.084
IgA/(g/L) 2.43 (1.75, 3.59) 2.01 (1.69, 2.86) 2.59 (1.80, 3.81) 0.172
IgG/(g/L) 11.95 (10.43, 13.30) 10.70 (9.77, 12.80) 12.40 (10.70, 14.30) 0.141
IgM/(g/L) 1.29 (0.82, 1.78) 1.22 (0.73, 1.51) 1.34 (0.92, 1.93) 0.310
RF/(IU/mL) 136.50 (31.28, 340.25) 133.00 (34.15, 404.50) 138.00 (28.00, 353.00) 0.984
ACPA/(U/mL) 144.57 (23.91, 200.00) 118.02 (63.96, 200.00) 155.81 (8.36, 200.00) 0.579
DAS28 4.74±1.26 4.52±1.35 4.85±1.22 0.385
CXCL9/(ng/L) 280.27 (150.50, 439.83) 149.90 (75.88, 257.72) 306.84 (234.02, 460.55) <0.001
CXCL10/(ng/L) 107.10 (52.62, 200.33) 54.43 (26.30, 83.69) 153.74 (89.50, 209.59) 0.001

Table 3

Multiple Logistic regression analysis of factors associated with RA patients with bone erosion"

Items β Wald OR 95%CI P value
Disease duration 0.015 6.550 1.015 1.003-1.026 0.010
ACPA -0.005 0.834 0.995 0.985-1.006 0.361
DAS28 1.063 4.539 2.896 1.089-7.701 0.033
CXCL9 0.011 8.339 1.012 1.004-1.019 0.004
CXCL10 -0.004 3.204 0.996 0.992-1.000 0.073
[1] Sparks JA. Rheumatoid arthritis [J]. Ann Intern Med, 2019, 170(1): ITC1-ITC16.
doi: 10.7326/AITC201901010
[2] Zhu H, Li R, Da Z, et al. Remission assessment of rheumatoid arthritis in daily practice in China: A cross-sectional observational study[J]. Clin Rheumatol, 2018, 37(3):597-605.
doi: 10.1007/s10067-017-3850-z
[3] Zhou Y, Wang X, An Y, et al. Disability and health-related quality of life in Chinese patients with rheumatoid arthritis: A cross-sectional study[J]. Int J Rheum Dis, 2018, 21(9):1709-1715.
doi: 10.1111/apl.2018.21.issue-9
[4] Poeta VM, Massara M, Capucetti A, et al. Chemokines and chemokine receptors: new targets for cancer immunotherapy[J]. Front Immunol, 2019, 10:379.
doi: 10.3389/fimmu.2019.00379
[5] Susek KH, Karvouni M, Alici E, et al. The role of CXC chemokine receptors 1-4 on immune cells in the tumor microenvironment[J]. Front Immunol, 2018, 9:2159.
doi: 10.3389/fimmu.2018.02159
[6] Tokunaga R, Zhang W, Naseem M, et al. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation: A target for novel cancer therapy[J]. Cancer Treat Rev, 2018, 63:40-47.
doi: S0305-7372(17)30199-8 pmid: 29207310
[7] McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis[J]. N Engl J Med, 2011, 365(23):2205-2219.
doi: 10.1056/NEJMra1004965
[8] Muntyanu A, Abji F, Liang K, et al. Differential gene and protein expression of chemokines and cytokines in synovial fluid of patients with arthritis[J]. Arthritis Res Ther, 2016, 18(1):296.
doi: 10.1186/s13075-016-1196-6
[9] Antonelli A, Ferrari SM, Giuggioli D, et al. Chemokine (C-X-C motif) ligand CXCL10 in autoimmune diseases[J]. Autoimmun Rev, 2014, 13(3):272-280.
doi: 10.1016/j.autrev.2013.10.010
[10] Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative[J]. Arthritis Rheum, 2010, 62(9):2569-2581.
doi: 10.1002/art.27584
[11] Zhang W, Doherty M, Peat G, et al. EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis[J]. Ann Rheum Dis, 2010, 69(3):483-489.
doi: 10.1136/ard.2009.113100 pmid: 19762361
[12] Prevoo ML, van’t Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis[J]. Arthritis Rheum, 1995, 38(1):44-48.
doi: 10.1002/art.v38:1
[13] Fransen J, van Riel PL. The disease activity score and the EULAR response criteria [J]. Rheum Dis Clin North Am, 2009, 35(4): 745-757, vii-viii.
doi: 10.1016/j.rdc.2009.10.001
[14] Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis[J]. Arthritis Rheum, 1988, 31(3):315-324.
doi: 10.1002/(ISSN)1529-0131
[15] Ostergaard M, Peterfy C, Conaghan P, et al. OMERACT rheumatoid arthritis magnetic resonance imaging studies. Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system[J]. J Rheumatol, 2003, 30(6):1385-1386.
[16] Bruyn GA, Hanova P, Iagnocco A, et al. Ultrasound definition of tendon damage in patients with rheumatoid arthritis. Results of a OMERACT consensus-based ultrasound score focusing on the diagnostic reliability[J]. Ann Rheum Dis, 2014, 73(11):1929-1934.
doi: 10.1136/annrheumdis-2013-203596
[17] Zeidler H. The need to better classify and diagnose early and very early rheumatoid arthritis[J]. J Rheumatol, 2012, 39(2):212-217.
doi: 10.3899/jrheum.110967
[18] Griffith JW, Sokol CL, Luster AD. Chemokines and chemokine receptors: Positioning cells for host defense and immunity[J]. Annu Rev Immunol, 2014, 32:659-702.
doi: 10.1146/annurev-immunol-032713-120145 pmid: 24655300
[19] Korniejewska A, McKnight AJ, Johnson Z, et al. Expression and agonist responsiveness of CXCR3 variants in human T lymphocytes[J]. Immunology, 2011, 132(4):503-515.
doi: 10.1111/j.1365-2567.2010.03384.x pmid: 21255008
[20] Schoenborn JR, Wilson CB. Regulation of interferon-gamma during innate and adaptive immune responses[J]. Adv Immunol, 2007, 96:41-101.
pmid: 17981204
[21] Farber JM. Mig and IP-10: CXC chemokines that target lymphocytes[J]. J Leukoc Biol, 1997, 61(3):246-257.
doi: 10.1002/jlb.1997.61.issue-3
[22] Kwak HB, Ha H, Kim HN, et al. Reciprocal cross-talk between RANKL and interferon-gamma-inducible protein 10 is responsible for bone-erosive experimental arthritis[J]. Arthritis Rheum, 2008, 58(5):1332-1342.
doi: 10.1002/(ISSN)1529-0131
[23] Kraan MC, Patel DD, Haringman JJ, et al. The development of clinical signs of rheumatoid synovial inflammation is associated with increased synjournal of the chemokine CXCL8 (interleukin-8)[J]. Arthritis Res, 2001, 3(1):65-71.
pmid: 11178128
[1] GAO Chao,CHEN Li-hong,WANG Li,YAO Hong,HUANG Xiao-wei,JIA Yu-bo,LIU Tian. Validation of the Pollard’s classification criteria (2010) for rheumatoid arthritis patients with fibromyalgia [J]. Journal of Peking University (Health Sciences), 2022, 54(2): 278-282.
[2] ZHANG Lu,HU Xiao-hong,CHEN Cheng,CAI Yue-ming,WANG Qing-wen,ZHAO Jin-xia. Analysis of cervical instability and clinical characteristics in treatment-naive rheumatoid arthritis patients [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1049-1054.
[3] LUO Liang,HUO Wen-gang,ZHANG Qin,LI Chun. Clinical characteristics and risk factors of rheumatoid arthritis with ulcerative keratitis [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1032-1036.
[4] LOU Xue,LIAO Li,LI Xing-jun,WANG Nan,LIU Shuang,CUI Ruo-mei,XU Jian. Methylation status and expression of TWEAK gene promoter region in peripheral blood of patients with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1020-1025.
[5] CAO Di,WANG Yan,WANG Liu-qing,SUN Xiao-lin,HUANG Fei,MENG Yang,REN Li-li,ZHANG Xue-wu. Expression of plasma Dickkopf-1 in patients with rheumatoid arthritis and its correlation with peripheral blood T cell subsets [J]. Journal of Peking University (Health Sciences), 2021, 53(2): 255-260.
[6] ZHAO Kai,CHANG Zhi-fang,WANG Zhi-hua,PANG Chun-yan,WANG Yong-fu. Therapeutic effect of gene silencing peptidyl arginine deaminase 4 on pulmonary interstitial lesions induced by collagen-induced arthritis mice [J]. Journal of Peking University (Health Sciences), 2021, 53(2): 235-239.
[7] Jia-li CHEN,Yue-bo JIN,Yi-fan WANG,Xiao-ying ZHANG,Jing LI,Hai-hong YAO,Jing HE,Chun LI. Clinical characteristics and risk factors of cardiovascular disease in patients with elderly-onset rheumatoid arthritis: A large cross-sectional clinical study [J]. Journal of Peking University (Health Sciences), 2020, 52(6): 1040-1047.
[8] Lu ZHANG,Xiao-hong HU,Qing-wen WANG,Yue-ming CAI,Jin-xia ZHAO,Xiang-yuan LIU. Population distribution and clinical characteristics in rheumatoid arthritis patients with cervical spine instability [J]. Journal of Peking University (Health Sciences), 2020, 52(6): 1034-1039.
[9] Guo TANG,Li LONG,Ya-xin HAN,Qing PENG,Jia-jun LIU,Hua SHANG. Clinical characteristics and related factors of rheumatoid arthritis complicated with tuberculosis infection [J]. Journal of Peking University (Health Sciences), 2020, 52(6): 1029-1033.
[10] Jing-feng ZHANG,Xiu-ling YE,Meng DUAN,Xiao-li ZHOU,Zhong-qiang YAO,Jin-xia ZHAO. Clinical and laboratory characteristics of rheumatoid arthritis with positive antinuclear antibody [J]. Journal of Peking University (Health Sciences), 2020, 52(6): 1023-1028.
[11] Jia-jing PENG,Tian LIU. Rheumatoid arthritis combined with pigmented villonodular synovitis: A case report and literature review [J]. Journal of Peking University (Health Sciences), 2020, 52(6): 1135-1139.
[12] Cai-nan LUO,Zheng-fang LI,Li-jun WU,Hai-juan CHEN,Chun-mei YANG,Wen-hui XU,Xiao-ling LIU,Wei TANG,Ping QIAO,Baihetiya Rena. Multicenter performance of the different classification criteria for rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2020, 52(5): 897-901.
[13] Hong ZHU,Li-juan ZHAO,Yan ZHOU,Yao CHEN. Significance of anti-carbamylated protein antibodies in patients with rheumatoid arthritis-associated intersitial lung disease [J]. Journal of Peking University(Health Sciences), 2019, 51(6): 1003-1007.
[14] Xiao-ying ZHANG,Jia-yang JIN,Jing HE,Yu-zhou GAN,Jia-li CHEN,Xiao-zhen ZHAO,Jia-jia LIU,Xu-jie YOU,Xue LI,Jian-ping GUO,Xiao-feng LI,Jing LI,Ru LI,Zhan-guo LI. Family history of rheumatic diseases in patients with rheumatoid arthritis: a large scale cross-sectional study [J]. Journal of Peking University(Health Sciences), 2019, 51(3): 439-444.
[15] Li WANG,Chao GAO,Di ZHU,Li-hong CHEN. Effect of functional exercises on patients with rheumatoid arthritis: a meta-analysis [J]. Journal of Peking University(Health Sciences), 2018, 50(6): 991-997.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] Author. English Title Test[J]. Journal of Peking University(Health Sciences), 2010, 42(1): 1 -10 .
[2] . [J]. Journal of Peking University(Health Sciences), 2009, 41(2): 188 -191 .
[3] . [J]. Journal of Peking University(Health Sciences), 2009, 41(3): 376 -379 .
[4] . [J]. Journal of Peking University(Health Sciences), 2009, 41(4): 459 -462 .
[5] . [J]. Journal of Peking University(Health Sciences), 2010, 42(1): 82 -84 .
[6] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 319 -322 .
[7] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 333 -336 .
[8] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 337 -340 .
[9] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 225 -328 .
[10] . [J]. Journal of Peking University(Health Sciences), 2007, 39(4): 346 -350 .
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd